9
18
7
↑9
↓18
—7
Evidence suggests Magnesium maydecreaseCholesterol accumulation.
19 studies (34 claims)
Emerging evidence
Typical effective dose 250 (250–250) mgacross 2 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| magnesium and zinc | Increases - significantly enhanced | HDL-cholesterol levels | Human | patients suffering from coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM) | — | The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease.cited 41× |
| dietary potassium magnesium sulphate (PMS) supplementation | Decreases - significantly reducing | cholesterol (CHO) levels | Animal | finishing pigs | 0.50% PMS added to the basal diet. | Preliminary Research on Dietary Supplementation of Potassium Magnesium Sulphate on Transport Stress in Finishing Pigs Prior to Slaughter. |
| dietary potassium magnesium sulphate (PMS) supplementation | Increases - significantly increased | high-density lipoprotein cholesterol (HDL-C) levels | Animal | finishing pigs | 0.50% PMS added to the basal diet. | Preliminary Research on Dietary Supplementation of Potassium Magnesium Sulphate on Transport Stress in Finishing Pigs Prior to Slaughter. |
| magnesium oxide 250 mg/day | Increases - significantly higher levels | HDL-cholesterol | Human | people with prediabetes | 250 mg/day of magnesium oxide. | Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.cited 11× |
| magnesium supplementation | Increases - increased | HDL-cholesterol levels | Human | people with prediabetes | 250 mg/day of magnesium oxide. | Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.cited 11× |
| magnesium supplementation | No effect - did not differ significantly | LDL-cholesterol | Human | people with prediabetes | 250 mg/day of magnesium oxide. | Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.cited 11× |
| magnesium supplementation | No effect - did not differ significantly | total cholesterol | Human | people with prediabetes | 250 mg/day of magnesium oxide. | Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.cited 11× |
| magnesium and vitamin E co-supplementation | Increases - increased | HDL-cholesterol | Human | patients with diabetic foot ulcer (DFU) | — | The effects of magnesium and vitamin E co-supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial.cited 47× |
| magnesium and vitamin E co-supplementation | Decreases - decreased | LDL-cholesterol | Human | patients with diabetic foot ulcer (DFU) | — | The effects of magnesium and vitamin E co-supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial.cited 47× |
| Magnesium and vitamin E co-supplementation | No effect - did not affect | HDL-cholesterol levels | Human | women with gestational diabetes (GDM) | — | The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes.cited 22× |
| magnesium plus vitamin E supplementation | Decreases - significant reduction in | LDL-cholesterol | Human | women with gestational diabetes (GDM) | — | The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes.cited 22× |
| magnesium plus vitamin E supplementation | Decreases - significant reduction in | total-cholesterol | Human | women with gestational diabetes (GDM) | — | The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes.cited 22× |
| magnesium plus vitamin E supplementation | Decreases - significant reduction in | total-/HDL-cholesterol ratio | Human | women with gestational diabetes (GDM) | — | The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes.cited 22× |
| magnesium plus vitamin E supplementation | Decreases - significant reduction in | VLDL-cholesterol | Human | women with gestational diabetes (GDM) | — | The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes.cited 22× |
| oral magnesium supplementation | Decreases - improved | cholesterol levels | Human | patients with metabolic syndrome | 400 mg of oral magnesium daily. | Positive effects of magnesium supplementation in metabolic syndrome. |
| oral magnesium supplementation | Increases - changes were significantly higher | high-density lipoprotein cholesterol | Human | individuals with MetS and hypomagnesemia | — | Oral Magnesium Supplementation and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial.cited 23× |
| oral magnesium supplementation | No effect - was not found to significantly affect | plasma concentrations of total cholesterol | Human | diabetic and non-diabetic individuals | Not specified in the abstract. | Effect of magnesium supplementation on lipid profile: a systematic review and meta-analysis of randomized controlled trials.cited 30× |
| magnesium supplementation | Increases - significantly increased | serum levels of high density lipoprotein cholesterol (HDL-C) | Human | general population aged ≥ 18 years | Not specified. | The effect of magnesium supplementation on serum concentration of lipid profile: an updated systematic review and dose-response meta-analysis on randomized controlled trials. |
| magnesium supplementation | No effect - showed no significant differences | serum levels of low density lipoprotein cholesterol (LDL-C) | Human | general population aged ≥ 18 years | Not specified. | The effect of magnesium supplementation on serum concentration of lipid profile: an updated systematic review and dose-response meta-analysis on randomized controlled trials. |
| magnesium supplementation | No effect - showed no significant differences | serum levels of total cholesterol (TC) | Human | general population aged ≥ 18 years | Not specified. | The effect of magnesium supplementation on serum concentration of lipid profile: an updated systematic review and dose-response meta-analysis on randomized controlled trials. |
| magnesium supplementation | No effect - No significant changes were observed | serum total cholesterol, triglycerides, HDL, LDL, and total cholesterol/HDL cholesterol ratio | Human | hypomagnesemic patients diagnosed with type 2 diabetes and early-stage nephropathy | — | Oral Magnesium Supplementation Improved Lipid Profile but Increased Insulin Resistance in Patients with Diabetic Nephropathy: a Double-Blind Randomized Controlled Clinical Trial.cited 23× |
| magnesium plus vitamin E supplementation | Decreases - A trend toward a greater decrease | total cholesterol levels | Human | women with PCOS | — | The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.cited 19× |
| magnesium plus vitamin E supplementation | Decreases - significantly decreased | VLDL-cholesterol concentrations | Human | women with PCOS | — | The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.cited 19× |
| magnesium | No effect - shows the effect | HDL-cholesterol | Human | — | Not specified | Magnesium in metabolic syndrome: a review based on randomized, double-blind clinical trials.cited 27× |
| magnesium- and potassium-based formulations | Decreases - overall decrease in cholesterol levels | cholesterol levels | Human | patients with T2DM | Not specified | Comparative Efficacy of Magnesium and Potassium Towards Cholesterol and Quality of Life in Patients With Type 2 Diabetes Mellitus: A Randomised Single-Blinded Controlled Clinical Trial.cited 1× |
| Selenium and magnesium co-supplementation | Increases - upregulation | cholesterol 7α-hydroxylase (CYP7A1) and lecithin cholesterol acyltransferase (LCAT) | Animal | hyperlipidemia rats | — | Effects of oral selenium and magnesium co-supplementation on lipid metabolism, antioxidative status, histopathological lesions, and related gene expression in rats fed a high-fat diet. |
| Selenium and magnesium co-supplementation | No effect - regulated | mRNA expression levels of liver enzymes related to cholesterol metabolism | Animal | hyperlipidemia rats | — | Effects of oral selenium and magnesium co-supplementation on lipid metabolism, antioxidative status, histopathological lesions, and related gene expression in rats fed a high-fat diet. |
| low-dose selenium and magnesium co-supplementation | Decreases - significantly reduced | elevated levels of serum and liver total cholesterol (TC) and serum LDL-C induced by feeding high-fat diets | Animal | hyperlipidemic rat model | — | Effects of oral selenium and magnesium co-supplementation on lipid metabolism, antioxidative status, histopathological lesions, and related gene expression in rats fed a high-fat diet. |
| magnesium-zinc-calcium-vitamin D co-supplementation | Decreases - significantly decreased | total cholesterol | Human | women with polycystic ovary syndrome (PCOS) | 100 mg magnesium, 4 mg zinc, 400 mg calcium, and 200 IU vitamin D twice daily | A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome.cited 15× |
| magnesium-zinc-calcium-vitamin D co-supplementation | Decreases - significantly decreased | total-/HDL-cholesterol ratio | Human | women with polycystic ovary syndrome (PCOS) | 100 mg magnesium, 4 mg zinc, 400 mg calcium, and 200 IU vitamin D twice daily | A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome.cited 15× |
| magnesium-zinc-calcium-vitamin D co-supplementation | Decreases - significantly decreased | VLDL-cholesterol concentrations | Human | women with polycystic ovary syndrome (PCOS) | 100 mg magnesium, 4 mg zinc, 400 mg calcium, and 200 IU vitamin D twice daily | A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome.cited 15× |
| magnesium-zinc-calcium-vitamin D co-supplementation | Decreases - significantly decreased | very-low-density-cholesterol concentrations | Human | patients with GDM | Not specified | Magnesium-zinc-calcium-vitamin D co-supplementation improves glycemic control and markers of cardiometabolic risk in gestational diabetes: a randomized, double-blind, placebo-controlled trial.cited 35× |
| magnesium supplements | Decreases - lead to lowering | total cholesterol | Human | patients with PCO | 250 mg/day of magnesium oxide. | The Effect of Magnesium Supplementation on Insulin Resistance and Metabolic Profiles in Women with Polycystic Ovary Syndrome: a Randomized Clinical Trial.cited 9× |